GB0219746D0 - Azapurine derivatives - Google Patents

Azapurine derivatives

Info

Publication number
GB0219746D0
GB0219746D0 GBGB0219746.5A GB0219746A GB0219746D0 GB 0219746 D0 GB0219746 D0 GB 0219746D0 GB 0219746 A GB0219746 A GB 0219746A GB 0219746 D0 GB0219746 D0 GB 0219746D0
Authority
GB
United Kingdom
Prior art keywords
azapurine derivatives
azapurine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0219746.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST OF EX BOTANY ASCR
Institute of Experimental Botany Academy CAS
Original Assignee
INST OF EX BOTANY ASCR
Institute of Experimental Botany Academy CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST OF EX BOTANY ASCR, Institute of Experimental Botany Academy CAS filed Critical INST OF EX BOTANY ASCR
Priority to GBGB0219746.5A priority Critical patent/GB0219746D0/en
Publication of GB0219746D0 publication Critical patent/GB0219746D0/en
Priority to EP03792601A priority patent/EP1539760A2/en
Priority to AU2003260919A priority patent/AU2003260919A1/en
Priority to JP2004530478A priority patent/JP2006511458A/ja
Priority to PCT/IB2003/004188 priority patent/WO2004018473A2/en
Priority to US11/051,059 priority patent/US7816350B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
GBGB0219746.5A 2002-08-23 2002-08-23 Azapurine derivatives Ceased GB0219746D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0219746.5A GB0219746D0 (en) 2002-08-23 2002-08-23 Azapurine derivatives
EP03792601A EP1539760A2 (en) 2002-08-23 2003-08-22 Azapurine derivatives
AU2003260919A AU2003260919A1 (en) 2002-08-23 2003-08-22 Azapurine derivatives
JP2004530478A JP2006511458A (ja) 2002-08-23 2003-08-22 アザプリン誘導体
PCT/IB2003/004188 WO2004018473A2 (en) 2002-08-23 2003-08-22 Azapurine derivatives
US11/051,059 US7816350B2 (en) 2002-08-23 2005-02-04 Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0219746.5A GB0219746D0 (en) 2002-08-23 2002-08-23 Azapurine derivatives

Publications (1)

Publication Number Publication Date
GB0219746D0 true GB0219746D0 (en) 2002-10-02

Family

ID=9942920

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0219746.5A Ceased GB0219746D0 (en) 2002-08-23 2002-08-23 Azapurine derivatives

Country Status (6)

Country Link
US (1) US7816350B2 (US20060035909A1-20060216-C00009.png)
EP (1) EP1539760A2 (US20060035909A1-20060216-C00009.png)
JP (1) JP2006511458A (US20060035909A1-20060216-C00009.png)
AU (1) AU2003260919A1 (US20060035909A1-20060216-C00009.png)
GB (1) GB0219746D0 (US20060035909A1-20060216-C00009.png)
WO (1) WO2004018473A2 (US20060035909A1-20060216-C00009.png)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
CA2531232A1 (en) 2003-07-16 2005-02-10 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
KR20060070572A (ko) * 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
DK2392564T3 (da) 2003-09-26 2014-01-13 Exelixis Inc c-Met-modulatorer og anvendelsesfremgangsmåder
EP1598354A1 (en) 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation
WO2006014325A2 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
ATE502931T1 (de) 2004-08-19 2011-04-15 Dsm Ip Assets Bv Verfahren zur rektifikation von vitamin e acetat
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
CA2577588C (en) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
ES2368338T3 (es) * 2004-12-27 2011-11-16 Novartis Ag Análogos de aminopirazina para el tratamiento del glaucoma y otras enfermedades mediadas por la rho cinasa.
WO2006076442A2 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
RU2007130893A (ru) * 2005-01-14 2009-02-20 Янссен Фармацевтика Н.В. (Be) Производные триазолопиримидина
NZ561939A (en) 2005-03-30 2011-03-31 Conforma Therapeutics Corp Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
GB0610317D0 (en) * 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
WO2008054796A2 (en) 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
US7566722B2 (en) 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
US9095578B2 (en) * 2007-01-12 2015-08-04 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2012044572A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
WO2012048265A2 (en) * 2010-10-08 2012-04-12 The Broad Institute Of Mit And Harvard Methods of treating inflammation
GB201506509D0 (en) 2015-04-16 2015-06-03 Univ Wageningen Nuclease-mediated genome editing
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
CN112313232B (zh) * 2018-05-02 2024-03-08 Jw中外制药公司 新型杂环衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5962595A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５，７―トリ置換―トリアゾロピリミジン誘導体
PL313973A1 (en) * 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
JP2000507552A (ja) * 1996-03-26 2000-06-20 デュポン ファーマシューティカルズ カンパニー アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1998028300A1 (en) * 1996-12-20 1998-07-02 Astra Pharmaceuticals Ltd. Triazolo[4,5-d]pyrimidinyl derivatives and their use as medicaments
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
DE69905451T2 (de) * 1998-02-17 2003-11-20 Astrazeneca Uk Ltd Neue triazolo(4,5d) pyrimidinverbindungen
DE19838705A1 (de) * 1998-08-26 2000-03-02 Bayer Ag Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one
SE0004099D0 (sv) * 2000-11-09 2000-11-09 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
EP1539760A2 (en) 2005-06-15
JP2006511458A (ja) 2006-04-06
WO2004018473A3 (en) 2004-05-21
US7816350B2 (en) 2010-10-19
WO2004018473A2 (en) 2004-03-04
US20060035909A1 (en) 2006-02-16
AU2003260919A1 (en) 2004-03-11
AU2003260919A8 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
AU2003260919A8 (en) Azapurine derivatives
HK1077068A1 (en) Azolidinone-vinyl fused-benzene derivatives
IL166121A0 (en) Indole-3-sulphur derivatives
EP1522540A4 (en) AZAARENE DERIVATIVES
PL376475A1 (en) N-substituted-2-oxodihydropyridine derivatives
ZA200500471B (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
AP2005003342A0 (en) Pyrrolopyrimidine derivatives
PL371918A1 (en) Pyridazine derivatives
PL372047A1 (en) Pyrrolopyrimidine derivatives
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
GB2382209B (en) Meeting aid
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
GB0213488D0 (en) 2-Naphthamide derivatives
AU2003243397A8 (en) Homo-camptothecin derivatives
AU150222S (en) Range
GB0215011D0 (en) Easy squeezy
GB0120583D0 (en) Azapurine derivatives
AU2003285777A8 (en) 3-substituted-4-pyrimidone derivatives
GB0210512D0 (en) Tetrahydro-napthalene derivatives
GB0221143D0 (en) Dihydropyridinone derivatives
TW532451U (en) Fast fitting
GB0227620D0 (en) Easy Klik
GB0213751D0 (en) Aid

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)